Outcomes improved with early concurrent immunotherapy and SRS in melanoma brain metastases

Specialists have reported significantly improved overall survival and distant brain failure-free survival in melanoma patients with brain metastases treated with early concurrent immunotherapy and stereotactic radiosurgery (SRS).

At the SNO 2020 virtual conference, Dr Alexander Augustyn from the University of Texas MD Andersen Cancer Center, in Houston, USA, presented data from a retrospective review of concurrent immunotherapy and SRS. Concurrent use was defined as SRS being performed within 30 days of immune checkpoint inhibitor (ICI) therapy.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.